Over the past decades, life expectancy of people with cystic fibrosis (CF) has significantly improved as a result of improved antimicrobial treatment, new therapies (such as the CFTR modulators), management strategies aimed at improving nutritional status and facilitating mucus clearance, and standardization of care in multidisciplinary CF centers [1, 2]. This evidence concerns the gene CFTR and cystic fibrosis.